Dark teal graphic titled Tumor Testing, with the subtitle What each appendix cancer test shows and what to ask your care team, beside amber and teal rings.

Appendix Cancer Tumor Testing: What Each Test Shows

Appendix cancer tumor testing looks for changes in the DNA of a tumor, and sometimes in the DNA you were born with, that can affect treatment, clinical trial options and family risk. The 2025 consensus guidelines from the Peritoneal Surface Malignancy (PSM) Consortium say everyone with appendix cancer that has spread should have their tumor tested with next-generation sequencing, a broad genetic test.

Most people with appendix cancer hear about testing in pieces. A surgeon mentions tumor markers. An oncologist orders a blood test called ctDNA. Someone brings up inherited risk. Each test answers a different question, and a result from one does not stand in for the others. This page lays out the main kinds of appendix cancer tumor testing, what each one can and cannot tell you, and where our deeper articles on each one live.

Everything here follows the 2025 consensus guidelines from the PSM Consortium, led by Dr. Elizabeth Godfrey and colleagues. Sources are listed at the bottom.

Tumor testing and germline testing are different tests

Tumor testing, also called somatic or genomic testing, reads the DNA of the cancer itself. It looks for changes the tumor picked up as it grew, such as mutations in KRAS or GNAS. Those results can point toward a targeted drug or a clinical trial.

Germline testing reads the DNA you were born with, usually from a blood or saliva sample. It looks for inherited changes you could share with your children or siblings. A 2024 guideline from the American Society of Clinical Oncology (ASCO) says people who meet the criteria for germline testing should be offered it no matter what their tumor test showed. The PSM Consortium guidelines say germline testing should be considered as indicated. Our post on appendix cancer genetic testing explains what a germline result means for a family.

Next-generation sequencing of the tumor

Next-generation sequencing, or NGS, checks hundreds of genes in a sample of tumor tissue at once. The 2025 guidelines say everyone with appendix cancer that has spread should have their tumor tested with NGS.

The changes found most often in appendix cancer are in KRAS and GNAS, especially in mucinous tumors. A 2026 study from Dr. John Paul Shen’s lab at MD Anderson found KRAS mutations in about 79 percent of mucinous appendiceal adenocarcinomas, with a version called G12D the most common. The exact version matters, because new drugs are built for specific ones. Our targeted therapy guide covers what those drugs are.

For appendiceal mucinous neoplasms such as LAMN and HAMN, the guidelines say tumor testing may be considered, and that there is little evidence yet on how the results should change treatment. Testing can still give you a baseline and possible trial eligibility. Our post on appendix cancer mutation testing explains why tissue testing is worth doing even after a negative blood test.

A report that says “no actionable targets” or “wild type” does not mean the tumor has no mutations. It means nothing the lab found matched an approved drug or an open trial on the day of the report. Our post on wild type appendix cancer shows how to read that line, and our post on the appendix cancer genomic report explains what newer single-cell research adds beyond a list of mutations. For a look at how mutations differ by subtype and stage, see what your tumor type’s molecular profile can tell you.

MMR, MSI and TMB

Three results on a report deal with how well a tumor repairs its own DNA. Mismatch repair (MMR) testing stains the tumor for four repair proteins. Microsatellite instability (MSI) testing looks for the damage left behind when that repair fails. Tumor mutational burden (TMB) counts how many mutations the tumor carries. A high MSI or TMB result, or missing MMR proteins, can make someone eligible for immunotherapy.

MSI-high results are rare in appendix cancer, and the tests do not always agree with each other. Our posts on MSI testing in appendix cancer and appendix cancer biomarker testing walk through what to do when two results conflict.

Markers that work across cancer types

Some drugs are approved for a tumor marker rather than for a body part. A 2026 review counted nine of these FDA approvals since 2017, covering six markers: MSI-high or MMR deficiency, high TMB, NTRK fusions, RET fusions, BRAF V600E, and HER2 at the strongest staining level (IHC 3+). If an appendix tumor carries one of these markers, an approved drug may apply without a trial. Whether it does depends on your stage, your past treatment and the exact wording of the label. Only a test can show whether a tumor carries one of them.

If you already have a report, our free Drug Match tool shows which FDA-approved drugs connect to the mutations on it, how strong the evidence is, and what to ask your oncologist. Nothing you enter is saved.

Blood tests: tumor markers and ctDNA

Tumor marker blood tests measure proteins that some appendix tumors release. The three used most are CEA, CA 19-9 and CA-125, and the 2025 guidelines include them in the workup after diagnosis. They are most useful when tracked over time. Our posts on appendix cancer blood tests, tumor markers before and after CRS and CA-125 testing in men cover what the numbers can and cannot tell you.

Circulating tumor DNA, or ctDNA, is tumor DNA found in the blood. It is a separate test from tissue sequencing, and a negative ctDNA result does not mean tissue testing has nothing to offer, especially in low-grade disease. For LAMN, the 2025 guidelines do not recommend ctDNA for follow-up scans and visits. Our posts on ctDNA and surgery decisions and getting all of your ctDNA data go further.

Save tissue before surgery

Every tissue test depends on having tissue. Standard pathology preserves tumor in wax blocks, which work for DNA testing but kill the cells. Some research tests, including drug-response testing on living tumor cells, need fresh tissue handled a special way on the day of surgery, and that has to be arranged in advance. If surgery is coming, ask your team before the date what will happen to your tumor. Our posts on preserving tumor tissue and the question most patients never ask before surgery list the questions to bring.

Questions to ask your care team

  • Has my tumor had next-generation sequencing, and can I have a copy of the full report?
  • Should I have germline testing, and has anyone talked with my family about it?
  • Were MMR and MSI both tested, and do the results agree?
  • Does anything on my report match an approved drug or an open clinical trial?
  • If I have surgery coming, can tissue be saved for future testing or research?

For help with the pathology side of your report, see understanding your pathology and the glossary.

Add your testing reports to the registry

The Appendicure Patient-Led Global Appendix Cancer Registry collects pathology, genomic, and molecular reports from people with every appendiceal cancer type. Pooling those reports is how researchers learn which mutations matter for which subtypes. It is IRB-reviewed, free, and open worldwide. Please use the form for where you live.

Already enrolled? Add new reports or correct your record.

Frequently asked questions about appendix cancer tumor testing

What is the difference between tumor testing and germline testing?

Tumor testing reads the DNA of the cancer and looks for changes the tumor picked up as it grew. Germline testing reads the DNA you were born with and looks for inherited changes you could pass to your children. One does not replace the other.

Does everyone with appendix cancer need next-generation sequencing?

The 2025 PSM Consortium guidelines say everyone with appendix cancer that has spread should have their tumor tested with next-generation sequencing. For appendiceal mucinous neoplasms such as LAMN and HAMN, they say testing may be considered.

What does wild type mean on my report?

Wild type means the test did not find a mutation in the genes it checked. It does not mean the tumor has no mutations, and it does not mean drugs built for wild type colon cancer will work.

Can a ctDNA blood test replace testing my tumor tissue?

No. A ctDNA blood test and a tissue test answer different questions, and a negative ctDNA result does not mean tissue testing has nothing to offer.

Is MSI-high common in appendix cancer?

No. MSI-high results are rare in appendix cancer. Ruling it out is still worth doing, because an MSI-high result can make someone eligible for immunotherapy.

Sources

  • Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 1: Appendiceal tumors without peritoneal involvement. Cancer. 2025;131(13):e35867. doi.org/10.1002/cncr.35867
  • Godfrey EL, Mahoney F, Bansal VV, et al. Consensus guideline for the management of patients with appendiceal tumors, part 2: Appendiceal tumors with peritoneal involvement. Cancer. 2025;131(13):e35874. doi.org/10.1002/cncr.35874
  • Chowdhury S, Ito I, Pattalachinti VK, et al. KRAS inhibition is an effective therapy for appendiceal adenocarcinoma. J Hematol Oncol. 2026;19:70. doi.org/10.1186/s13045-026-01817-3
  • Jones DT, Nanda RK, Hussain AA, et al. Evaluating tissue-agnostic approvals in thoracic and head and neck malignancies. Cancers. 2026;18(5):856. doi.org/10.3390/cancers18050856
  • Tung N, Ricker C, Messersmith H, et al. Selection of germline genetic testing panels in patients with cancer: ASCO guideline. J Clin Oncol. 2024;42(21):2599-2615. doi.org/10.1200/JCO.24.00662

Each linked Appendicure article lists the full citations for the studies it covers.

Medically reviewed by Michael Foote, MD, Medical Oncologist & Physician-Scientist, Memorial Sloan Kettering. This page was written with AI assistance. It is for education and does not replace advice from your own care team. Last updated November 2026.